Market Place
Sourcing Support
All News #Library
Biotech
Sagimet Bio Reports 2025 Financials And Corporate Updates
11 Mar 2026 //
GLOBENEWSWIRE
Sagimet Bio To Participate In 3 Upcoming Investor Conferences
25 Feb 2026 //
GLOBENEWSWIRE
Sagimet Bio To Participate In 2 Upcoming Investor Conferences
05 Feb 2026 //
GLOBENEWSWIRE
Sagimet Announces Positive 52-Wk Denifanstat Data in Severe MASH
02 Feb 2026 //
GLOBENEWSWIRE
Sagimet Biosciences Presents Poster At MASH-TAG 2026 Conference
08 Jan 2026 //
GLOBENEWSWIRE
Sagimet Biosciences Reports Positive Phase 1 Results in PK Trial
18 Dec 2025 //
GLOBENEWSWIRE
Ascletis Accepts Denifanstat NDA For Moderate To Severe Acne
10 Dec 2025 //
GLOBENEWSWIRE
Sagimet Biosciences Announces Grants Under Nasdaq Rule 5635(c)(4)
09 Dec 2025 //
GLOBENEWSWIRE
Sagimet Biosciences to Participate in 8th Evercore ISI Conference
20 Nov 2025 //
GLOBENEWSWIRE
Sagimet Biosciences Showcases Two Denifanstat Posters at AASLD
10 Nov 2025 //
GLOBENEWSWIRE
Denifanstat Meets All Ph3 Endpoints in Moderate to Severe Acne
24 Oct 2025 //
GLOBENEWSWIRE
Sagimet Initiates Phase 1 Pk Trial For Denifanstat & Resmetirom
01 Oct 2025 //
GLOBENEWSWIRE
Sagimet Bio Participation at Fierce Biotech Week Panel
24 Sep 2025 //
GLOBENEWSWIRE
Sagimet Completes End-of-Ph 2 Interactions with FDA for Denifanstat
29 Oct 2024 //
GLOBENEWSWIRE
Sagimet To Present At 8th Annual MASH Drug Development Summit
12 Sep 2024 //
GLOBENEWSWIRE
Sagimet to Participate in Two Upcoming Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.